12:00 AM
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ocriplasmin regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 10-0 that the benefits of ThromboGenics' ocriplasmin from ThromboGenics outweigh the potential risks for the vitreomacular adhesion (VMA) treatment. The panel voted 10-0 that the product is effective for treating VMA, and 7-3 for treating macular holes associated...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >